Dipartimento di Anestesia, Rianimazione (Intensiva e Subintensiva) e Terapia del Dolore, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.
Crit Care. 2011;15(6):243. doi: 10.1186/cc10490. Epub 2011 Dec 8.
The H1N1 flu pandemic led to a wider use of extracorporeal membrane oxygenation (ECMO), proving its power in hypoxemic emergencies. The results obtained during this pandemic, more than any randomized trial, led to the worldwide acceptance of the use of membrane lungs. Moreover, as centers that applied this technique as rescue therapy for refractory hypoxemia recognized its strength and limited technical challenges, the indications for ECMO have recently been extended. Indications for veno-venous ECMO currently include respiratory support as a bridge to lung transplantation, correction of lung hyperinflation during chronic obstructive pulmonary disease exacerbation and respiratory support in patients with the acute respiratory distress syndrome, possibly also without mechanical ventilation. The current enthusiasm for ECMO in its various aspects should not, however, obscure the consideration of the potential complications associated with this life-saving technique, primarily brain hemorrhage.
甲型 H1N1 流感大流行导致体外膜氧合(ECMO)的广泛应用,证明了其在低氧血症急症中的强大作用。在这次大流行期间获得的结果,比任何随机试验都更能促使全世界接受使用膜肺。此外,由于应用该技术作为难治性低氧血症抢救治疗的中心认识到其优势和有限的技术挑战,ECMO 的适应证最近已得到扩展。目前,静脉-静脉 ECMO 的适应证包括作为肺移植桥接的呼吸支持、慢性阻塞性肺疾病恶化期间肺过度充气的纠正以及急性呼吸窘迫综合征患者的呼吸支持,可能也无需机械通气。然而,目前对 ECMO 各个方面的热情不应掩盖对与这种救命技术相关的潜在并发症的考虑,主要是脑出血。